Researchers in the laboratory of Zhiqiang An, Ph.D., are working on innovative treatments for cancer and other human diseases. In particular, they are developing targeted treatments involving the use of proteins called antibodies that can be engineered to latch onto tumor cells and disrupt their growth. These drugs are associated with fewer side effects. An’s research is supported by the Cancer Prevention & Research Institute of Texas, the National Institutes of Health and the pharmacy industry. Prior to joining the faculty of the UTHealth Medical School, An served as an executive in the biotechnology and pharmaceutical industry. An received his Ph.D. degree from the University of Kentucky, Lexington, and his postdoctoral training at the University of Wisconsin-Madison.
Amitava Dasgupta, Ph.D., is a toxicologist whose research interests include addressing misconceptions about herbal supplements. He has published 198 papers in peer-reviewed journals and has written three consumer health books. In addition, he has written two reference books on toxicology and edited or co-edited another 10 reference books. In 2009, he received the Irvine Sunshine Award from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology for his outstanding contributions in clinical toxicology research.
Previous interview: http://abclocal.go.com/wtvd/story?section=news/health/health_watch&id=8215693